Israeli ADHD-Drug Maker Alcobra Seeks $27 Million in IPO

Alcobra Pharma, an Israeli company developing an oral medicine with reduced side effects to treat attention deficit hyperactivity disorder, filed to raise as much as $27.3 million in a Nasdaq initial public offering.

Alcobra plans to sell 2.27 million shares in a price range of $10 to $12 a share to fund work on the drug, according to a filing on the U.S. Securities and Exchange Commission website. Aegis Capital Corp. was hired as sole bookrunner while Sunrise Securities Corp. is co-manager.

ADHD affects 3 percent to 5 percent of school-age children, mostly boys, according to the National Institutes of Health. Alcobra said that, in contrast to most current amphetamine medications with “significant” side effects, the Tel Aviv- based drugmaker’s MG01CI treatment showed no detectable changes in appetite, sleep patterns or mood in a mid-stage clinical study in 120 adults.

The market for pharmaceutical treatments for ADHD in 2012 is estimated to exceed $3.8 billion in the U.S., Alcobra said. The company plans to use the proceeds of the stock sale to finance two advanced-stage trials in the U.S. estimated to cost $6 million each, it said.

To contact the reporter on this story: David Wainer in Tel Aviv at

To contact the editor responsible for this story: Phil Serafino at

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.